TheraRadar
← Back
Data updated: Jul 17, 2026

INDICUS PHARMA

Generics

INDICUS PHARMA is a generic drug manufacturer focused on Cardiovascular, Neurology, Ophthalmology.

2008
Since
4
Drugs
-
Trials
0
New Drugs (2yr)

INDICUS PHARMA's Key Drugs

INDICUS PHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

INDICUS PHARMA's Recent FDA Approvals

New NDA/BLA approvals for INDICUS PHARMA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

INDICUS PHARMA's Therapeutic Areas

INDICUS PHARMA's approved drugs and pipeline span 3 therapeutic areas, led by Cardiovascular and Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 33%
1 drugs
Neurology 33%
1 drugs
Ophthalmology 33%
1 drugs

INDICUS PHARMA's Top Competitors

INDICUS PHARMA's closest competitors by therapeutic-area and drug-target overlap include Novartis, UPJOHN, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

INDICUS PHARMA Pipeline Snapshot

Active clinical trials for INDICUS PHARMA across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling